Beth Hoffman

Beth Hoffman

Company: Origami Therapeutics

Job title: CEO

Seminars:

Closing Remarks 5:20 pm

Read more

day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

Panel Discussion: Demonstrating Degrader Efficacy 4:25 pm

• What is the challenge behind demonstrating degrader efficacy? • What methods are currently followed to overcome the challenge of showing degrader targeting to the protein of interest? • Establishing correlation between ubiquitination and target degradation, in vitro and in cell system remains a challenge. Tackling this problem will be key to establishing structure-activity relationship…Read more

day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

Adapting Targeted Protein Degradation for Neurological Disorders 4:00 pm

• Special considerations for the CNS • Selecting the appropriate type of degrader • Challenges in determining efficacy in the CNSRead more

day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

Opening Remarks 3:00 pm

Read more

day: Agenda: TPD: Emerging Disease Applications Beyond Oncology

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.